Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment

Trial Profile

Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Biomarker; Pharmacodynamics
  • Acronyms AVA-CELL
  • Most Recent Events

    • 18 Aug 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 02 Feb 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Jun 2015.
    • 21 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top